Adrafinil is a prodrug: it is pharmacologically inactive or weakly active in its parent form and exerts its primary effects through hepatic conversion to modafinil.supported
Review of modafinil (and prodrug adrafinil) chemical, PK, PD, toxicological aspects. 08897077.2019.1700584
Adrafinil is a prodrug: it is pharmacologically inactive or weakly active in its parent form and exerts its primary effects through hepatic conversion to modafinil.supported
Adrafinil metabolized to active modafinil in vivo. 20961790.2019.1704482
Adrafinil itself has been classified as an alpha-1 adrenergic receptor agonist by NCATS, supported by early pharmacological work demonstrating that adrafinil could not antagonize yohimbine-induced toxicity in mice (unlike the alpha-2 agonist clonidine), consistent with alpha-1 central stimulant activitysupported
Adrafinil described as alpha-1 central stimulant. Adrafinil could not antagonize yohimbine toxicity (unlike clonidine alpha-2 agonist). Suggests adrafinil acts via central alpha-1 adrenergic mechanism. pmid:2906156
Claim in pharmacology — inconclusiveinconclusiveworking →
However, the Milgram et al. (1999) review of adrafinil states that "the underlying mechanisms of action are still unknown" for adrafinil specifically, a caveat echoed by Siwak et al. (2000)supported
Underlying mechanisms of action still unknown. pmid:11191710
In healthy male humans, modafinil at 200–400 mg occupies 47–70% of DAT in the caudate, putamen, and nucleus accumbens as measured by [¹¹C]cocaine positron emission tomography, accompanied by increases in extracellular dopaminesupported
modafinil at 200mg and 400mg blocked dopamine transporters (DAT) in caudate, putamen, and nucleus accumbens in human brain, with 47-70% occupancy... potential for increased extracellular dopamine. jama.2009.351
The in vivo wake-promoting potency of modafinil correlates significantly with its in vitro DAT affinity (and not NET affinity) in canine narcolepsy modelssupported
In vivo potencies of DA uptake inhibitors and modafinil on wake significantly correlated with in vitro affinities to DA transporter. pmid:11382857
Electrophysiological and amperometric studies in wild-type versus cocaine-insensitive DAT knock-in mice confirm that modafinil potentiates dopaminergic signals strictly via DAT, acting at the same binding site as cocainesupported
Modafinil inhibits dopamine transporter (DAT). Acts at same binding site as cocaine. Potentiates brain dopaminergic signals via DAT inhibition. j.neuroscience.2013.07.071
Armodafinil (R-modafinil) also occupies DAT and releases striatal dopamine in humans, confirmed by PET.supported
Armodafinil (R-modafinil, the R-enantiomer of modafinil) occupies DAT and releases striatal dopamine in humans. PET confirmation of dopaminergic mechanism. j.biopsych.2010.08.026
Secondary mechanisms attributed to modafinil include norepinephrine reuptake inhibition (NET), upstream activation of orexin/hypocretin systems, histaminergic pathway activation, serotonin release, increased glutamate, and decreased GABAsupported
Major effects: dopamine reuptake inhibition plus modulation of noradrenergic, serotoninergic, orexinergic, histaminergic, glutamatergic and GABAergic pathways. 08897077.2019.1700584
Secondary mechanisms attributed to modafinil include norepinephrine reuptake inhibition (NET), upstream activation of orexin/hypocretin systems, histaminergic pathway activation, serotonin release, increased glutamate, and decreased GABAsupported
Modafinil may increase wakefulness through activation of noradrenergic and dopaminergic systems, possibly through interaction with hypocretin/orexin system. Complex multi-target mechanism. pmid:15532213
Secondary mechanisms attributed to modafinil include norepinephrine reuptake inhibition (NET), upstream activation of orexin/hypocretin systems, histaminergic pathway activation, serotonin release, increased glutamate, and decreased GABAsupported
Additional actions on GABA, glutamate, serotonin, norepinephrine. Unique pharmacology. bs.apha.2023.10.006
Unlike amphetamine-class stimulants, modafinil does not cause direct monoamine release via reverse transport — the DAT occupancy mechanism is blockade only, which explains the lower reinforcement potential and abuse liability.supported
Modafinil inhibits dopamine transporter. Few cases of dependence vs other psychostimulants. Unique pharmacology. bs.apha.2023.10.006
Unlike amphetamine-class stimulants, modafinil does not cause direct monoamine release via reverse transport — the DAT occupancy mechanism is blockade only, which explains the lower reinforcement potential and abuse liability.supported
Modafinil enhances wakefulness without affecting reinforcement, devoid of addictive potential. DAT inhibition via VTA/NAc/thalamic pathways. Distinguishes modafinil from addictive psychostimulants. fnana.2025.1670564
Adrafinil is converted in the liver to modafinil (active) and modafinilic acid (inactive)supported
Review of modafinil (and prodrug adrafinil)... Modafinil is a racemate metabolized mainly in the liver into inactive acid and sulfone metabolites. 08897077.2019.1700584
Adrafinil is converted in the liver to modafinil (active) and modafinilic acid (inactive)supported
Adrafinil metabolized to active modafinil in vivo. 20961790.2019.1704482
In a human self-administration study, a single oral 200 mg dose of adrafinil was followed by detection of both adrafinil (0.8 ng/mg) and modafinil (0.5 ng/mg) in beard hair at 10 days post-administration, confirming prodrug conversion in humanssupported
After oral 200mg adrafinil: adrafinil 0.8 ng/mg in hair, modafinil 0.5 ng/mg. 20961790.2019.1704482
Both the parent compound and metabolites (modafinil, modafinil acid) are detectable in human urine by LC-MS/MS.supported
LC/MS/MS method for adrafinil and metabolites (modafinil, modafinil acid) in human urine. rcm.4044
Rat pharmacokinetic studies confirmed oral bioavailability and characterized serum kinetics of adrafinilsupported
Pharmacokinetics of adrafinil in rats by LC-MS/MS... Oral administration to rats. j.jchromb.2008.07.025
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →